KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Debt (2016 - 2025)

Jazz Pharmaceuticals has reported Total Debt over the past 16 years, most recently at $5.4 billion for Q4 2025.

  • Quarterly Total Debt fell 12.28% to $5.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 billion through Dec 2025, down 12.28% year-over-year, with the annual reading at $5.4 billion for FY2025, 12.28% down from the prior year.
  • Total Debt was $5.4 billion for Q4 2025 at Jazz Pharmaceuticals, roughly flat from $5.4 billion in the prior quarter.
  • Over five years, Total Debt peaked at $6.7 billion in Q2 2021 and troughed at $2.1 billion in Q1 2021.
  • The 5-year median for Total Debt is $5.7 billion (2023), against an average of $5.6 billion.
  • Biggest five-year swings in Total Debt: skyrocketed 220.39% in 2021 and later dropped 12.28% in 2025.
  • Tracing JAZZ's Total Debt over 5 years: stood at $6.0 billion in 2021, then fell by 5.38% to $5.7 billion in 2022, then decreased by 0.2% to $5.7 billion in 2023, then increased by 6.93% to $6.1 billion in 2024, then fell by 12.28% to $5.4 billion in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $5.4 billion, $5.4 billion, and $5.4 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.